Exelixis at All-Time High – Patent Victory Protects Cabometyx and Zanzalintinib as Billion-Dollar Opportunity

Exelixis has specialized as a biotechnology company in the research, development, and marketing of targeted cancer therapies. Cabometyx continues to be the growth driver and increased global franchise revenues in Q2 by 13% to $806 million. Confirmed Cabozantinib patents prevent MSN generics from reaching the market before 2030. Zanzalintinib could become the second major product franchise in colorectal cancer. Exelixis (EXEL) remains a leader stock in the biotech sector with a market capitalization of $15.5 billion and a stock performance...